Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized…
First-and-only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale…